TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
In the four-year CATCH trial, patients with uncontrolled hypertension at clinics in Jamaica and Colombia had better blood pressure control when offered a pill combining two or three medications alongside team-based support. The findings, published in JAMA and presented at the 2026 American Heart Association Scientific Sessions, add long-term evidence for the approach, but do not establish its effects on major clinical outcomes such as heart attacks or strokes.
A four-year trial in Jamaica and Colombia found that patients with uncontrolled high blood pressure had better control when treated with single pills combining two or three medicines than with usual care that added medications over time. The findings, published in JAMA and presented at the 2026 American Heart Association Scientific Sessions, provide longer-term evidence for an approach already recommended in treatment guidelines.
The cluster-randomized CATCH trial recruited 1,706 patients at 40 primary care clinics in Jamaica and Colombia. Clinics were assigned to usual stepped care or a program built around a single-pill combination. In stepped care, patients generally began with one blood pressure drug, with clinicians increasing the dose or adding other medicines if their pressure remained high.
Patients in the single-pill group received a tablet containing two or three antihypertensive medicines. The program also included nurse instruction on measuring blood pressure at home, study-provided equipment, regular review of readings and health-coach support for medication adherence. The comparison was therefore between care strategies, not simply between one tablet and several tablets.
At 18 months, average systolic pressure had fallen by about 19 points in the single-pill group, compared with about nine points under standard care. Nearly 70% of the single-pill group reached the trial’s target of below 130 mm Hg systolic and below 80 mm Hg diastolic, compared with 29% in the standard-care group. Six months after the trial ended, 75% of intervention-group patients were still receiving the combination through insurance or government programs and maintained better control, the report said.
Evidence Beyond Short-Term Trials
The findings address a gap in evidence for long-term blood pressure control. Earlier trials had found that single-pill combinations could lower pressure more quickly than multi-pill regimens, but many lasted only weeks. The CATCH results suggest the strategy can be maintained beyond the initial treatment period when paired with practical support such as home monitoring and adherence coaching.
That matters because uncontrolled hypertension increases the risk of cardiovascular disease, stroke and chronic kidney disease. The report cited estimates that blood pressure is controlled in 22.5% of U.S. patients with hypertension and 13.6% in low- and middle-income countries. These figures describe the scale of the problem, not the effect of the trial intervention on those populations overall.
Study co-leader Jiang He of UT Southwestern Medical Center said the program could be implementable and scalable in resource-constrained settings and could inform care in the United States and elsewhere. However, the trial measured blood pressure control, not whether the strategy reduces heart attacks, strokes, deaths or other major clinical outcomes.
Products Worth Considering
Withings BPM Connect Blood Pressure Monitor with Wi-Fi and Bluetooth
Withings BPM Vision Blood Pressure Monitor with Wi-Fi and Bluetooth
Blueair Blue Pure 211i Max Air Purifier for Large Rooms
As an affiliate, we earn on qualifying purchases.
Guidelines and Treatment Uptake
U.S. and international guidelines recommend single-pill combination therapy as a preferred strategy for many patients who need more than one medication. Combining drugs in one tablet can simplify the daily regimen, while stepped care typically begins with one drug and adds or adjusts medicines as needed.
Despite those recommendations, He said about 10% of U.S. patients with hypertension are treated with single-pill combinations. The report cited physician surveys suggesting that unfamiliarity with the option and limited evidence from large, long-term trials may contribute to its relatively low use. The CATCH study was designed to address part of that evidence gap, with a four-year trial conducted through primary care clinics in two countries.
The trial received funding from the U.S. National Heart, Lung, and Blood Institute. Its results were reported in JAMA and presented during the American Heart Association’s 2026 Scientific Sessions.
“Our study demonstrated that a single-pill combination provided an effective, implementable, scalable, and sustainable approach for hypertension control in low- and middle-income countries.”
— Jiang He, study co-leader and professor at UT Southwestern Medical Center
Clinical Outcomes Still Need Study
The reported results do not show whether single-pill treatment reduces heart attacks, strokes, kidney failure or deaths compared with usual care. He said further large clinical trials assessing clinical outcomes are needed. The source report also does not provide detailed results on adverse events or explain how blood pressure control changed at every point across the full four-year trial period.
The intervention combined medication with home monitoring, nursing follow-up and health coaching, so the reported difference cannot be attributed to the pill format alone. It is also unclear from the report how results might vary in other health systems, among patients with different characteristics, or where access to the combination medicines and follow-up support differs.
Further Trials and Wider Adoption
The next research step identified by the study’s co-leader is larger trials testing whether single-pill combinations improve clinical outcomes, not only blood pressure readings. Such evidence could help clinicians and patients weigh the strategy’s benefits across different settings.
The trial report does not announce a specific next study or a timetable for new results. For now, the findings add evidence for guideline-recommended treatment, while decisions about medication remain a matter for patients and their health professionals.
Key Questions
What did the CATCH trial compare?
It compared usual stepped care, in which medicines were adjusted or added over time, with a program using one pill containing two or three blood pressure medicines. The single-pill program also included home monitoring and adherence support.
How much did blood pressure change?
At 18 months, average systolic pressure fell by about 19 points in the single-pill group and about nine points in the standard-care group. These are group averages reported by the study.
Where and how many people took part?
The trial enrolled 1,706 patients with uncontrolled hypertension at 40 primary care clinics in Jamaica and Colombia.
Does the study prove the treatment prevents heart attacks or strokes?
No. The reported findings concern blood pressure control. The study’s co-leader said further large trials are needed to assess effects on clinical outcomes such as heart attacks and strokes.
Was the improvement due to taking only one pill?
The trial tested a broader care program that combined the pill with home blood pressure monitoring, nurse review and health-coach support. The results do not isolate the effect of the pill format from those other parts of the program.
Source: news-medical.net
